Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Operating Leases (2022 - 2026)

Rani Therapeutics Holdings' Operating Leases history spans 5 years, with the latest figure at $2.5 million for Q1 2026.

  • On a quarterly basis, Operating Leases fell 27.52% to $2.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.5 million, a 27.52% decrease, with the full-year FY2025 number at $2.7 million, down 24.88% from a year prior.
  • Operating Leases came in at $2.5 million for Q1 2026, down from $2.7 million in the prior quarter.
  • The five-year high for Operating Leases was $4.7 million in Q1 2024, with the low at $59000.0 in Q4 2022.
  • Historically, Operating Leases has averaged $2.1 million across 5 years, with a median of $2.6 million in 2025.
  • Biggest five-year swings in Operating Leases: plummeted 46.23% in 2023 and later surged 2249.12% in 2024.
  • Year by year, Operating Leases stood at $59000.0 in 2022, then soared by 189.83% to $171000.0 in 2023, then skyrocketed by 2026.9% to $3.6 million in 2024, then fell by 24.88% to $2.7 million in 2025, then decreased by 9.19% to $2.5 million in 2026.
  • Business Quant data shows Operating Leases for RANI at $2.5 million in Q1 2026, $2.7 million in Q4 2025, and $3.0 million in Q3 2025.